Oncolytics Biotech Inc reported continued advancement of its lead immunotherapy candidate pelareorep during the first quarter of 2026. The company is focusing on registration-enabling trials for gastrointestinal cancers, notably metastatic colorectal and anal cancers where pelareorep has demonstrated promising response rates above standard therapies. However, the firm faces significant financial constraints with limited cash resources and a pressing need for additional funding to sustain operations beyond the near term. Its proprietary oncolytic virus platform underpins a differentiated position in the competitive immuno-oncology landscape, but successful commercialization will depend on achieving regulatory approvals and securing strategic partnerships.